CeriBell, Inc. (NASDAQ:CBLL) Receives $32.14 Average PT from Brokerages

CeriBell, Inc. (NASDAQ:CBLL) has received a consensus recommendation of “Moderate Buy” from the nine analysts that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation and eight have given a buy recommendation to the company. The average 12-month target price among analysts that have covered the stock in the last year is $32.1429.

Several equities analysts have recently issued reports on CBLL shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of CeriBell in a report on Saturday, September 27th. BTIG Research started coverage on CeriBell in a report on Tuesday, June 24th. They issued a “buy” rating and a $30.00 target price on the stock.

CeriBell Price Performance

CBLL opened at $12.64 on Friday. CeriBell has a 12-month low of $10.01 and a 12-month high of $32.75. The company has a market cap of $463.38 million and a price-to-earnings ratio of -4.23. The company has a current ratio of 13.31, a quick ratio of 12.91 and a debt-to-equity ratio of 0.11. The stock has a fifty day simple moving average of $12.30 and a two-hundred day simple moving average of $15.45.

CeriBell (NASDAQ:CBLL) last issued its quarterly earnings results on Tuesday, August 5th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.02. CeriBell had a negative net margin of 63.83% and a negative return on equity of 48.42%. The company had revenue of $21.20 million during the quarter, compared to analyst estimates of $20.52 million. CeriBell has set its FY 2025 guidance at EPS. Research analysts predict that CeriBell will post -2.46 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of CBLL. KLP Kapitalforvaltning AS bought a new position in shares of CeriBell in the first quarter worth approximately $36,000. Tower Research Capital LLC TRC raised its holdings in CeriBell by 353.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock worth $43,000 after acquiring an additional 1,801 shares during the last quarter. Ameritas Investment Partners Inc. raised its holdings in CeriBell by 97.5% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,544 shares of the company’s stock worth $48,000 after acquiring an additional 1,256 shares during the last quarter. New York State Common Retirement Fund bought a new position in CeriBell in the 1st quarter valued at approximately $67,000. Finally, Police & Firemen s Retirement System of New Jersey increased its holdings in shares of CeriBell by 161.0% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 5,677 shares of the company’s stock worth $106,000 after purchasing an additional 3,502 shares in the last quarter.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.